Patents by Inventor Tal Teitz

Tal Teitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240307400
    Abstract: This disclosure provides for methods, kits and pharmaceutical compositions comprising an inhibitor of EGFR signaling for the treatment of hearing loss. In particular, one such EGFR inhibitor, Dabrafenib, is a therapeutic candidate for treating cisplatin-induced and/or noise-induced hearing loss.
    Type: Application
    Filed: May 28, 2024
    Publication date: September 19, 2024
    Inventors: Jian ZUO, Tal TEITZ
  • Patent number: 12053446
    Abstract: Oseltamivir is used as active agent to treat a hearing impairment and to prevent a hearing impairment, and a method of treating and/or preventing hearing impairments or disorders using Oseltamivir are disclosed. Oseltamivir exhibits excellent protection against noise-induced hearing loss and against cisplatin-induced hearing loss.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: August 6, 2024
    Assignees: Ting Therapeutics LLC, St Jude Children's Research Hospital
    Inventors: Tal Teitz, Jian Zuo, Taosheng Chen
  • Publication number: 20240139315
    Abstract: Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.
    Type: Application
    Filed: December 15, 2023
    Publication date: May 2, 2024
    Inventors: Jian ZUO, Fei ZHENG, Tetsuji YAMASHITA, Zoe KELLARD, Tal TEITZ, Jaeki MIN, Taosheng CHEN
  • Patent number: 11883491
    Abstract: Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: January 30, 2024
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Jian Zuo, Fei Zheng, Tetsuji Yamashita, Zoe Kellard, Tal Teitz, Jaeki Min, Taosheng Chen
  • Publication number: 20230000881
    Abstract: In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: July 12, 2022
    Publication date: January 5, 2023
    Applicant: St. Jude Children's Research Hospital
    Inventors: Jian Zuo, Tal Teitz, Fang Jie, Goktug Asli, Chen Taosheng, Min Jaeki, R. Kiplin Guy
  • Publication number: 20220265660
    Abstract: Method, kit and pharmaceutical compositions using an inhibitor of EGFR signaling for prevention or treatment of hearing loss are described.
    Type: Application
    Filed: May 4, 2022
    Publication date: August 25, 2022
    Applicant: Ting Therapeutics LLC
    Inventors: Jian Zuo, Tal Teitz
  • Publication number: 20220133730
    Abstract: Method, kit and pharmaceutical compositions using an inhibitor of EGFR signaling for prevention or treatment of hearing loss are described.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 5, 2022
    Applicant: Ting Therapeutics LLC
    Inventors: Jian Zuo, Tal Teitz
  • Publication number: 20200179397
    Abstract: In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: December 9, 2019
    Publication date: June 11, 2020
    Inventors: Jian Zuo, Tal Teitz, Jie Fang, Asli Goktug, Taosheng Chen, Jaeki Min, R. Kiplin Guy
  • Publication number: 20200093923
    Abstract: Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.
    Type: Application
    Filed: April 30, 2018
    Publication date: March 26, 2020
    Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITALEINDHOVEN
    Inventors: Jian Zuo, Fei Zheng, Tetsuji Yamashita, Zoe Kellard, Tal Teitz, Jaeki Min, Taosheng Chen
  • Patent number: 7052834
    Abstract: The present invention relates to identification of tumor suppressor activity of a protein, caspase-8 (CASP8), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation that results from genomic methylation of the promoter. In particular, CASP8 is functionally inactivated in greater than 90% of all MYCN amplified neuroblastoma cell lines analyzed. Inactivation of CASP8 was observed to occur by homozygous deletion, heterozygous deletion coupled with gene silencing by methylation, and homozygous gene silencing by methylation. A PCR methylation analysis for inactivation of CASP8 is described.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: May 30, 2006
    Assignee: St. Jude Children's Research Hospital
    Inventors: Vincent J. Kidd, Jill M. Lahti, Tal Teitz